Monoclonal Antibodies are mono-specific antibodies bodies having identical immune cells which are clones of a single parent cell and are directed to specific cellular targets.
Therefore, Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. Hence, monoclonal antibodies technology is proved to be more effective than other cancer therapies.
The market growth is driven by several factors such as the rising incidence of cancer patients and growing investments by the companies in the research and development of genomic studies. The market is also driven by the specificity of the nature of monoclonal antibodies to target only cancer cells. However, the market is negatively affected by the high costs involved in the development of these advanced techniques and regulatory issues faced by the countries for the rolling out of these products.
The largest part of cancer immunotherapies involved monoclonal antibodies as monoclonal antibodies having more potential to offer less toxic and efficient therapy to the patients. They are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer.
Based on anitobodies, the market is segmented into Humanized, Murine, Rat, Chimeric, Human, Immunotoxin, Immunoadhesin, and Others.
Based on Applications, the market is segmented into Non-small-cell lung cancers, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Glioma cancer, Bladder Cancer, Lymphoma, Ovarian Cancer, and Others.
Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW.
North America dominates the global cancer monoclonal antibodies market due to the well-established healthcare infrastructures, increased spending by the government for infection control and management, and the rising prevalence of lifestyle-related diseases.
In 2015, the US government spent US 13.6 billion to execute the above-mentioned activities. This region is expected to show growth owing to the rise in funding by the government for cancer research and technology development.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
